https://observatorio.fm.usp.br/handle/OPI/11787
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | ZANETTI, Marcus V. | - |
dc.contributor.author | OTADUY, Maria C. | - |
dc.contributor.author | SOUSA, Rafael T. de | - |
dc.contributor.author | GATTAZ, Wagner F. | - |
dc.contributor.author | BUSATTO, Geraldo F. | - |
dc.contributor.author | LEITE, Claudia C. | - |
dc.contributor.author | MACHADO-VIEIRA, Rodrigo | - |
dc.date.accessioned | 2015-10-26T16:31:59Z | - |
dc.date.available | 2015-10-26T16:31:59Z | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, v.18, n.6, 2015 | - |
dc.identifier.issn | 1461-1457 | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/11787 | - |
dc.description.abstract | Background: The hippocampus has been highly implicated in the pathophysiology of bipolar disorder (BD). Nevertheless, no study has longitudinally evaluated hippocampal metabolite levels in bipolar depression under treatment with lithium. Methods: Nineteen medication-free BD patients (78.9% treatment-naive and 73.7% with BD type II) presenting an acute depressive episode and 17 healthy controls were studied. Patients were treated for 6 weeks with lithium in an open-label trial. N-acetyl aspartate (NAA), creatine, choline, myo-Inositol, and glutamate levels were assessed in the left hippocampus before (week 0) and after (week 6) lithium treatment using 3T proton magnetic resonance spectroscopy (1H-MRS). The metabolite concentrations were estimated using internal water as reference and voxel segmentation for partial volume correction. Results: At baseline, acutely depressed BD patients and healthy controls exhibited similar hippocampal metabolites concentrations, with no changes after 6 weeks of lithium monotherapy. A significant correlation between antidepressant efficacy and increases in NAA concentration over time was observed. Also, there was a significant positive correlation between the changes in glutamate concentrations over follow-up and plasma lithium levels at endpoint. Mixed effects model analysis revealed a bimodal effect of lithium plasma levels in hippocampal glutamate concentrations: levels of 0.2 to 0.49 mmol/L (n=9) were associated with a decrease in glutamate concentrations, whereas the subgroup of BD subjects with ""standard"" lithium levels (>= 0.50 mmol/L; n = 10) showed an overall increase in glutamate concentrations over time. Conclusions: These preliminary results suggest that lithium has a bimodal action in hippocampal glutamate concentration depending on the plasma levels. | - |
dc.description.sponsorship | Sao Paulo Research Foundation (FAPESP, Brazil) [2009/14891-9] | - |
dc.description.sponsorship | Associacao Beneficente Alzira Denise Hertzog da Silva (ABADHS) | - |
dc.description.sponsorship | FAPESP, Brazil [2013/03905-4] | - |
dc.language.iso | eng | - |
dc.publisher | OXFORD UNIV PRESS | - |
dc.relation.ispartof | International Journal of Neuropsychopharmacology | - |
dc.rights | restrictedAccess | - |
dc.subject | bipolar disorder | - |
dc.subject | depression | - |
dc.subject | glutamate | - |
dc.subject | hippocampus | - |
dc.subject | lithium | - |
dc.subject | magnetic resonance spectroscopy | - |
dc.subject.other | magnetic-resonance-spectroscopy | - |
dc.subject.other | mood disorders | - |
dc.subject.other | rating-scale | - |
dc.subject.other | human brain | - |
dc.subject.other | pathophysiology | - |
dc.subject.other | plasticity | - |
dc.subject.other | schizophrenia | - |
dc.subject.other | metaanalysis | - |
dc.subject.other | monotherapy | - |
dc.subject.other | expression | - |
dc.title | Bimodal Effect of Lithium Plasma Levels on Hippocampal Glutamate Concentrations in Bipolar II Depression: A Pilot Study | - |
dc.type | article | - |
dc.rights.holder | Copyright OXFORD UNIV PRESS | - |
dc.identifier.doi | 10.1093/ijnp/pyu058 | - |
dc.identifier.pmid | 25522399 | - |
dc.subject.wos | Clinical Neurology | - |
dc.subject.wos | Neurosciences | - |
dc.subject.wos | Pharmacology & Pharmacy | - |
dc.subject.wos | Psychiatry | - |
dc.type.category | original article | - |
dc.type.version | publishedVersion | - |
hcfmusp.description.issue | 6 | - |
hcfmusp.description.volume | 18 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | WOS:000356700000002 | - |
hcfmusp.origem.id | 2-s2.0-84939199013 | - |
hcfmusp.publisher.city | OXFORD | - |
hcfmusp.publisher.country | ENGLAND | - |
hcfmusp.relation.reference | Amsterdam JD, 2008, J CLIN PSYCHOPHARM, V28, P171, DOI 10.1097/JCP.0b013e318166c4e6 | - |
hcfmusp.relation.reference | Beneyto M, 2007, NEUROPSYCHOPHARMACOL, V32, P1888, DOI 10.1038/sj.npp.1301312 | - |
hcfmusp.relation.reference | Bustillo Juan R, 2013, Dialogues Clin Neurosci, V15, P329 | - |
hcfmusp.relation.reference | Capizzano AA, 2007, J MAGN RESON IMAGING, V26, P1378, DOI 10.1002/jmri.21144 | - |
hcfmusp.relation.reference | Colla M, 2009, MOL PSYCHIATR, V14, P696, DOI 10.1038/mp.2008.26 | - |
hcfmusp.relation.reference | Dager Stephen R, 2008, Top Magn Reson Imaging, V19, P81, DOI 10.1097/RMR.0b013e318181e0be | - |
hcfmusp.relation.reference | Du J, 2010, P NATL ACAD SCI USA, V107, P11573, DOI 10.1073/pnas.0913138107 | - |
hcfmusp.relation.reference | Ende G, 2000, ARCH GEN PSYCHIAT, V57, P937, DOI 10.1001/archpsyc.57.10.937 | - |
hcfmusp.relation.reference | First M., 1995, STRUCTURED CLIN INTE | - |
hcfmusp.relation.reference | Frye MA, 2007, NEUROPSYCHOPHARMACOL, V32, P2490, DOI 10.1038/sj.npp.1301387 | - |
hcfmusp.relation.reference | Gasparovic C, 2006, MAGN RESON MED, V55, P1219, DOI 10.1002/mrm.20901 | - |
hcfmusp.relation.reference | Gigante AD, 2012, BIPOLAR DISORD, V14, P478, DOI 10.1111/j.1399-5618.2012.01033.x | - |
hcfmusp.relation.reference | Gigante AD, 2014, WORLD J BIOL PSYCHIA, V15, P145, DOI 10.3109/15622975.2013.819120 | - |
hcfmusp.relation.reference | Guy W, 1976, ECDEU ASSESSMENT MAN, P218 | - |
hcfmusp.relation.reference | HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56 | - |
hcfmusp.relation.reference | HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800 | - |
hcfmusp.relation.reference | Howells FM, 2013, PROG NEURO-PSYCHOPH, V41, P1, DOI 10.1016/j.pnpbp.2012.10.026 | - |
hcfmusp.relation.reference | Khairova R, 2012, MOL MED REP, V5, P680, DOI 10.3892/mmr.2011.732 | - |
hcfmusp.relation.reference | Kleindienst N, 2005, EUR ARCH PSY CLIN N, V255, P72, DOI 10.1007/s00406-005-0574-x | - |
hcfmusp.relation.reference | Konradi C, 2011, ARCH GEN PSYCHIAT, V68, P340, DOI 10.1001/archgenpsychiatry.2010.175 | - |
hcfmusp.relation.reference | Kraguljac NV, 2012, PSYCHIAT RES-NEUROIM, V203, P111, DOI 10.1016/j.pscychresns.2012.02.003 | - |
hcfmusp.relation.reference | Machado-Vieira R, 2014, EXP THER MED, V8, P1205, DOI 10.3892/etm.2014.1864 | - |
hcfmusp.relation.reference | Machado-Vieira R, 2009, BIPOLAR DISORD, V11, P92, DOI 10.1111/j.1399-5618.2009.00714.x | - |
hcfmusp.relation.reference | Machado-Vieira R, 2014, WORLD J BIOL PSYCHIA, V15, P84, DOI 10.3109/15622975.2013.830775 | - |
hcfmusp.relation.reference | Machado-Vieira R, 2012, PHARMACOL BIOCHEM BE, V100, P678, DOI 10.1016/j.pbb.2011.09.010 | - |
hcfmusp.relation.reference | McCullumsmith RE, 2007, BRAIN RES, V1127, P108, DOI 10.1016/j.brainres.2006.09.011 | - |
hcfmusp.relation.reference | Phillips M, 2008, MOL PSYCHIATR, V13, P833, DOI 10.1038/mp.2008.65 | - |
hcfmusp.relation.reference | Phillips ML, 2014, AM J PSYCHIAT, V171, P829, DOI 10.1176/appi.ajp.2014.13081008 | - |
hcfmusp.relation.reference | Posse S, 2007, MAGN RESON MED, V58, P236, DOI 10.1002/mrm.21287 | - |
hcfmusp.relation.reference | PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604 | - |
hcfmusp.relation.reference | Quiroz JA, 2008, NEUROPSYCHOPHARMACOL, V33, P2551, DOI 10.1038/sj.npp.1301671 | - |
hcfmusp.relation.reference | Rybakowski JK, 1999, J PSYCHIAT RES, V33, P363, DOI 10.1016/S0022-3956(99)00014-X | - |
hcfmusp.relation.reference | Senaratne R, 2009, PSYCHIAT RES-NEUROIM, V172, P205, DOI 10.1016/j.pscychresns.2008.07.007 | - |
hcfmusp.relation.reference | Soeiro-de-Souza MG, 2012, ACTA PSYCHIAT SCAND, V126, P332, DOI 10.1111/j.1600-0447.2012.01889.x | - |
hcfmusp.relation.reference | Suppes T, 2008, J AFFECT DISORDERS, V111, P334, DOI 10.1016/j.jad.2008.02.004 | - |
hcfmusp.relation.reference | Teicher MH, 2012, P NATL ACAD SCI USA, V109, pE563, DOI 10.1073/pnas.1115396109 | - |
hcfmusp.relation.reference | Wansapura JP, 1999, JMRI-J MAGN RESON IM, V9, P531, DOI 10.1002/(SICI)1522-2586(199904)9:4<531::AID-JMRI4>3.0.CO;2-L | - |
hcfmusp.relation.reference | Watson S, 2004, BRIT J PSYCHIAT, V184, P496, DOI 10.1192/bjp.184.6.496 | - |
hcfmusp.relation.reference | Young AH, 2010, J CLIN PSYCHIAT, V71, P150, DOI 10.4088/JCP.08m04995gre | - |
hcfmusp.relation.reference | YOUNG RC, 1978, BRIT J PSYCHIAT, V133, P429, DOI 10.1192/bjp.133.5.429 | - |
hcfmusp.relation.reference | Yuksel C, 2010, BIOL PSYCHIAT, V68, P785, DOI 10.1016/j.biopsych.2010.06.016 | - |
hcfmusp.relation.reference | Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424 | - |
dc.description.index | MEDLINE | - |
dc.identifier.eissn | 1469-5111 | - |
hcfmusp.citation.scopus | 28 | - |
hcfmusp.scopus.lastupdate | 2024-03-29 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MDR Artigos e Materiais de Revistas Científicas - FM/MPS Artigos e Materiais de Revistas Científicas - HC/InRad Artigos e Materiais de Revistas Científicas - HC/IPq Artigos e Materiais de Revistas Científicas - LIM/21 Artigos e Materiais de Revistas Científicas - LIM/27 Artigos e Materiais de Revistas Científicas - LIM/44 |
File | Description | Size | Format | |
---|---|---|---|---|
art_ZANETTI_Bimodal_Effect_of_Lithium_Plasma_Levels_on_Hippocampal_2015.PDF Restricted Access | publishedVersion (English) | 1.25 MB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.